ECOG 6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer

20260 citationsJournal Articlegold Open Access

Authors

Chengwei Peng · Northwestern University

P. Catalano · Dana-Farber Cancer Institute

John Zalcberg · The Coordinating Center

Ann D. Thor · University of Colorado Denver

Louis M Weiner · Georgetown University

Janardan D. Khandekar · NorthShore University HealthSystem

Deirdre Jill Cohen ·

Abstract

In this phase II trial, raltitrexed did not show significant response rates in patients with advanced CRC. Due to limited ORR of raltitrexed, value of TS expression as a biomarker was inconclusive. No new safety signals for raltitrexed were demonstrated.

Topics & Keywords

Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer Colorectal Cancer Surgical Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Oncologist

DOI: 10.1093/oncolo/oyaf378

Field-Weighted Citation Impact: 0.00